Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 229   

Articles published

SNY 53.89 +0.36 (0.67%)
price chart
News on Boom: JPMorgan Chase & Co. (NYSE:JPM), Sanofi SA (ADR) (NYSE ...
Sanofi SA (ADR) (NYSE:SNY) vaccines separation, Sanofi Pasteur, declared the starting of a phase III clinical trial in India for its trial rotavirus vaccine, developed and making by its associate Shantha Biotechnics in Hyderabad, India.
Sanofi Responds To Bribery Allegations
Sanofi SA (ADR) (SNY) responded to allegations of bribery activity in the Middle East and Africa late Monday, stating that it has notified relevant US authorities about the issue and is conducting a private investigation into the matter.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Sanofi, Regeneron Release Data For Sinusitis Drug
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) have released positive data from a Phase IIa study for their investigational drug dupilumab.
Related articles »  
Quick Fact With News Roundup- Merck & Co., Inc. (NYSE:MRK), Sanofi SA (ADR ...
Regeneron Pharmaceuticals and Sanofi SA (ADR) (NYSE:SNY) declared that the first patients have been dosed in a Phase III clinical research of dupilumab, an investigational treatment that blocks IL-4 and IL-13 signaling in above eighteen years of aged ...
Related articles »  
Dengue Outbreak Hits China; Sanofi In Lead For Cure
(ADR) (FUJIY) to step forward with their respective anti-Ebola treatment therapies. The Ebola outbreak has claimed about 3,500 lives as of October 8. This might have brought out the pharmaceutical industry's human side.
Related articles »  
Investors Are Watching: Sanofi SA (ADR) (NYSE:SNY), General Motors ...
French drugmaker Sanofi SA (ADR) (NYSE:SNY)and its U.S. partner Regeneron said on Monday they had started a Phase III clinical study of their experimental drug dupilumab in patients with atopic dermatitis.
Sanofi SA Rating Reiterated by Zacks (SNY)  Ticker Report
Related articles »  
Trader's Recap : Sanofi SA (ADR) (NYSE:SNY), Microsoft Corporation (NASDAQ ...
Zacks reiterated their neutral rating on shares of Sanofi SA (ADR) (NYSE:SNY) in a research note released on Tuesday morning.
Related articles »  
Top News: Sanofi SA (ADR) (NYSE:SNY), Gilead Sciences Inc. (NASDAQ:GILD ...
On 30 September Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc. have released positive data from a Phase IIa study for their investigational drug dupilumab.
Shining on Major News : Sanofi SA (ADR) (NYSE:SNY), Exxon Mobil ...
Sanofi SA (ADR) (SNY) responded to allegations of bribery activity in the Middle East and Africa late Monday, stating that it has notified relevant US authorities about the issue and is conducting a private investigation into the matter.